Previous Webinar

Stephen M. Fuchs, is the interim Executive Director at the Institute for Protein Innovation (IPI). He has had a more than twenty year career broadly interested in understanding how protein structure dictates function. Much of this work focused specifically on how proteins, including antibodies, recognized post-translational modifications in proteins such as histones. He received his PhD in Biochemistry from the University of Wisconsin-Madison and prior to joining IPI, Steve was an Assistant Professor at Tufts University where his research lab focused on novel mechanisms of epigenetic regulation.

Simona Colantonio is an expert in mass spectrometry applied to biologically relevant molecules. She received her PhD in Pharmaceutical Sciences from la Sapienza University of Rome, Italy. In the early stages of her career, she worked at the Regina Elena National Cancer Institute of Rome, Italy studying pharmacokinetics of anti-cancer drugs. Later, she moved to Maryland where she became involved in serum biomarker discovery at SAIC-Frederick Inc. (now Leidos Biomedical Research). She is the Director of the Antibody Characterization Laboratory at the Frederick National Laboratory for Cancer Research since September 2019.

Meghan Rego received her PhD from the University of Rhode Island studying the molecular etiology of the cancer susceptibility syndrome, Fanconi Anemia. Before joining Addgene to help launch their viral vector service in 2016, Meghan worked at a variety of biotechnology and pharmaceutical companies focused on therapeutic biologics. In her current role as Director of Antibodies, Meghan is focused on building Addgene's recombinant antibody production and quality control platform. She is excited to bring high quality, open-access antibodies to scientists.